Ozempic & Belly Fat: Biomarkers, Genetics, and Compounded Alte...

Last reviewed: May 25, 2026

Last updated: May 25, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Yes, GLP-1 medications including Ozempic may help reduce both visceral and subcutaneous abdominal fat, but the extent of fat loss varies widely among individuals. Clinical evidence suggests GLP-1 agonists reduce belly fat through appetite suppression and metabolic changes, though targeted spot reduction is not guaranteed.

Understanding why some people respond better to GLP-1 therapy than others requires looking beyond weight alone. PlexusDx supports precision medicine by combining biomarker data and genetic predispositions in peptide pathways with clinical assessment, helping patients and providers make informed decisions about GLP-1 options.

How GLP-1 Medications Target Abdominal Fat Distribution

GLP-1 agonists work by activating the glucagon-like peptide-1 receptor, which slows gastric emptying, reduces hunger signals, and may improve insulin sensitivity. This combination can lead to preferential loss of visceral fat—the metabolically harmful fat stored around organs—which is a key driver of metabolic dysfunction.

Research indicates that GLP-1 therapy reduces visceral adipose tissue more significantly than subcutaneous fat in some patients. This distinction matters because visceral fat is more strongly linked to insulin resistance, inflammation, and cardiovascular risk, making its reduction clinically meaningful beyond aesthetic concerns.

Individual Response Variation: Why Belly Fat Loss Differs Between Patients

Not all patients achieve the same degree of abdominal fat reduction on GLP-1 therapy. Factors including baseline metabolic rate, insulin sensitivity, GLP-1 receptor sensitivity, diet adherence, physical activity, and genetic predispositions all influence how much visceral fat an individual loses during treatment.

Factor Influencing Response	Clinical Relevance
GLP-1 Receptor Sensitivity (GLP1R Variants)	Genetic variations like rs6923761 may affect how efficiently your cells respond to GLP-1 signaling, potentially influencing fat loss outcomes
Baseline Visceral Adiposity and Metabolic Health	Patients with higher baseline visceral fat and insulin resistance often see more pronounced fat reduction than those with metabolic health closer to target
FTO Gene Polymorphisms (rs9939609)	Associated with appetite regulation and fat accumulation patterns; variants may influence how readily abdominal fat mobilizes during therapy
GIPR Co-receptor Expression (rs1800437)	Variant status can affect dual GIP/GLP-1 peptide response; important when considering combination peptide protocols like GLP-Squared
Lifestyle and Adherence Factors	Diet quality, exercise consistency, sleep, and stress management significantly amplify or limit GLP-1-mediated fat loss, regardless of genetics

Visceral vs. Subcutaneous Fat Loss: What the Evidence Shows

Clinical trials with Ozempic and other GLP-1 agonists show that weight loss is typically distributed across both visceral and subcutaneous compartments, though visceral fat reduction tends to occur earlier and more consistently. In the STEP trials for semaglutide, patients achieved an average 10-15% body weight loss within 68 weeks, with measurable improvements in metabolic markers.

Importantly, the distribution of fat loss depends on individual baseline body composition and metabolic state. Some patients may see preferential reduction in belly fat first, while others experience more uniform fat loss. This unpredictability underscores why assessing your unique genetic and metabolic profile before starting therapy can support more realistic expectations.

Who Benefits Most and When to Reassess Treatment Approach

GLP-1 therapy is typically recommended for individuals with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities such as type 2 diabetes, hypertension, or dyslipidemia. Abdominal adiposity in particular—measured by waist circumference—is a strong indicator that GLP-1 therapy may benefit metabolic health, independent of overall BMI.

If you do not see meaningful belly fat reduction after 3-6 months of consistent GLP-1 therapy at therapeutic dosing, it may signal that your GLP-1 receptor sensitivity is suboptimal, adherence barriers exist, or an alternative peptide approach (such as a dual GIP/GLP-1 agonist) warrants discussion with your provider. Genetic context from a Precision Peptide test can help guide that conversation.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context around your individual predisposition to GLP-1 and GIP receptor signaling by examining variants in GLP1R, GIPR, FTO, and MC4R. These results should be interpreted with a qualified healthcare provider and used alongside clinical assessment, metabolic biomarkers, and lifestyle factors—not as a standalone predictor of medication response.

The test reveals genetic predispositions in peptide metabolic pathways, helping you and your provider understand whether your baseline biology may favor stronger GLP-1 responsiveness, dual-peptide protocols like GLP-Squared, or microdose approaches. Knowing these predispositions can support a more informed discussion about compounded semaglutide, tirzepatide, or combination peptide options tailored to your unique metabolism.

When combined with baseline labs (fasting glucose, insulin, lipid panel, visceral adiposity markers), genetic insight from the Precision Peptide test can help your provider select the most appropriate compounded peptide protocol and anticipate adjustments if initial response to therapy is suboptimal. This precision-medicine approach reduces trial-and-error and may accelerate achievement of your fat-loss and metabolic health goals.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.